CADQAS undertakes research and development to evaluate and ensure the quality and accuracy of new diagnostic and predictive tests (biomarkers) before they are used clinically to identify groups of cancer patients suitable for targeted drug therapy.
Such quality assurance is crucial to ensure that the right patients are identified correctly for a given cancer treatment.
CADQAS develops appropriate testing material and trains health professionals in the performance and accurate interpretation of new diagnostic and predictive tests (biomarkers).
CADQAS is independent and works with all manufacturers of diagnostic and predictive tests and equipment. It provides training on a range of cancer diagnostic tests on a number of different platforms.